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WHAT THIS PAPER ADDS
 The claim of a reduction in abdominal aortic aneurysm (AAA) growth rate with statin therapy is based on low-quality evidence and
was not found to be signiﬁcant on meta-analysis of a few high-quality observational studies. Based on the present updated meta-
analysis, statin therapy is likely effective in the prevention of growth of small AAAs. Statin therapy may be more beneﬁcial in
reducing growth rate as the baseline diameter increases.a r t i c l e i n f o
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Objective: To determine whether statin therapy reduces the growth rate of small abdominal aortic
aneurysms (AAAs).
Design: A meta-analysis and a meta-regression of comparative studies.
Materials: Eligible studies were randomized controlled trials or observational comparative studies of
statin therapy versus placebo or no statin, enrolling individuals with small (<55 mm in diameter) AAAs
and reporting AAA growth rate as an outcome.
Methods: Study-speciﬁc estimates (standardized mean differences [SMDs]) were combined in the ﬁxed-
and random-effects model.
Results: Seven adjusted and 4 unadjusted observational comparative studies enrolling 4647 patients with
a small AAA were identiﬁed. Pooled analysis of all 11 studies suggested a signiﬁcant reduction in AAA
growth rate among patients assigned to statin therapy versus no statin (SMD, 0.420; 95% conﬁdence
interval [CI], 0.651 to 0.189). Combining the 7 high-quality studies providing adjusted data for growth
rates generated an attenuated but still statistically signiﬁcant result favoring statin therapy (SMD,
0.367; 95% CI, 0.566 to 0.168). The meta-regression coefﬁcient for the baseline diameter was
statistically signiﬁcant (0.096; 95% CI, 0.132 to 0.061).
Conclusion: Statin therapy is likely effective in prevention of the growth of small AAAs, and may be more
beneﬁcial as the baseline diameter increases.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Although several studies have found an association between the
presence of an abdominal aortic aneurysm (AAA) and total
cholesterol,1,2 there is no clear relationship between total choles-
terol and AAA growth rate.3e5 Despite this, there is evidence fromtions on this paper, please go
: þ81 559 75 2725.
ciety for Vascular Surgery. Publishea number of studies to suggest that statins may inﬂuence aneurysm
growth rates, presumably via these pleiotropic effects.6 Previous
meta-analyses6e11 of a small number (7) of observational
comparative studies also suggest a reduction in AAA growth rate in
patients taking a statin. This claim, however, is based on low-
quality evidence and was not signiﬁcant on meta-analysis of only
4 high-quality studies.10 On the other hand, based on our most
recent preliminary meta-analysis11 of another set of 4 high-quality
studies, we found that statin therapy is associated with lower
growth rate in patients with a small AAA. Herein, we report thed by Elsevier Ltd. All rights reserved.
H. Takagi et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 287e292288results of an updated formal meta-analysis of comparative studies
of statin therapy for reduction of AAA growth rate. To assess the
impact of initial diameter of AAA or percentage of female patients
on AAA growth rates, we also performed a meta-regression
analysis.
Material and Methods
Search strategy
All randomized controlled trials and observational comparative
studies of statin therapy enrolling patients with small AAAs were
identiﬁed using a 2-level search strategy. First, public domain
databases, including MEDLINE, EMBASE, and the Cochrane Central
Register of Controlled Trials, were searched through February 2012
using Web-based search engines (PubMed, OVID). Keywords
included abdominal aortic aneurysm; and statin, hydrox-
ymethylglutaryl-CoA reductase inhibitor, atorvastatin, cerivastatin,
ﬂuvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvas-
tatin, or simvastatin. Second, relevant studies were identiﬁed
through a manual search of secondary sources including references
of initially identiﬁed articles and a search of reviews and
commentaries. All references were downloaded for consolidation,
elimination of duplicates, and further analysis.
Study selection and data abstraction
Studies considered for inclusion met the following criteria: the
design was a randomized controlled trial or observational
comparative study; the study population was patients with a small
(<55 mm in diameter) AAA; patients were assigned to statin
therapy versus placebo or no statin; and outcomes included AAA
growth rate. Data regarding detailed inclusion criteria, duration of
follow-up, and AAA growth rates were abstracted (as available)
from each individual study. When adjusted growth rates or
adjusted mean differences (MDs) of growth rates were available,
they were extracted preferentially instead of crude (unadjusted)
data for growth rates. Where standard deviations (SDs) were
unavailable, missing SDs were imputed according to the Cochrane
Handbook.12
Statistical analysis
For each study, data regarding AAA growth rates were used to
generate standardized MDs (SMDs) and 95% conﬁdence intervals
(CIs). Study-speciﬁc estimates combined using inverse variance-
weighted averages of logarithmic SMDs in the ﬁxed- and
random-effects model. Between-study heterogeneity was analyzed
by means of standard c2 tests. Where nonsigniﬁcant statistical
heterogeneity was identiﬁed, the ﬁxed-effect estimate was used
preferentially as the summary measure. Sensitivity analyses were
performed to assess the contribution of each study to the pooled
estimate by excluding individual studies one at a time and recal-
culating the pooled SMD estimates for the remaining studies. To
assess the impact of baseline AAA diameter or female percentage
among the studies on the study-speciﬁc estimate, we performed
a restricted maximum likelihood meta-regression analysis. Meta-
regression graphs depict the effect of statin therapy on the
outcome (plotted as a SMD of growth rates on the y-axis) as
a function of a given factor (plotted as a mean of the baseline
diameter or a female percentage on the x-axis). Meta-regression
coefﬁcients (slopes of meta-regression lines) show the estimated
increase in SMD per unit increase in the covariate. A negative
coefﬁcient would indicate that as a given factor increases the SMD
decreases, i.e. statin therapy is more beneﬁcial in reducing theoutcome of interest. Publication bias was assessed graphically using
a funnel plot and mathematically using an adjusted rank-
correlation test. All analyses were conducted using the metareg in
Stata SE release 11.2 (StataCorp LP, College Station, TX) and
Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ).
Results
Search results
Initial electronic search identiﬁed 113 potentially relevant
publications, all of which were reviewed in detail. As a conse-
quence, we selected 4 unadjusted and 7 adjusted observational
comparative studies of statin therapy enrolling patients with
a small AAA.13e23 No randomized controlled trial was identiﬁed. In
total, our meta-analysis included data on 4647 patients assigned to
statin therapy or no statin. The trial design, female percentage,
follow-up duration, baseline diameter, growth rate, and their MDs
are summarized in Table 1.
Primary meta-analysis
Pooled analysis of all the 11 studies demonstrated a statistically
signiﬁcant reduction in AAA growth rates with statin therapy
relative to no statin in the random-effects model (SMD, 0.420;
95% CI, 0.651 to 0.189; P < 0.001; P for heterogeneity <0.001;
Fig. 1). To assess publication bias, we generated a funnel plot of the
effect size versus the precision (reciprocal of the standard error) for
each study (Fig. 2). There was no evidence of signiﬁcant publication
bias (P ¼ 0.276).
Sensitivity analysis
To assess the impact of qualitative heterogeneity in study
design and patient selection on the pooled effect estimate, we
performed several sensitivity analyses. First, we excluded 4 low-
quality studies13e15,21 reporting unadjusted growth rates.
Combining the remaining 7 high-quality studies providing
adjusted data for growth rates generated an attenuated but still
statistically signiﬁcant result favoring statin therapy (random-
effects SMD, 0.367; 95% CI, 0.566 to 0.168; P < 0.001; P for
heterogeneity ¼ 0.005; Fig. 3). In general, exclusion of any single
study from the analysis did not substantively alter the overall result
of our analysis (Fig. 4).
Meta-regression analysis
Meta-regression analysis was performed to determine whether
the effects of statin therapy were modulated by the pre-speciﬁed
factors. The meta-regression coefﬁcient for the female percentage
(slope of the meta-regression line) was not statistically signiﬁcant
(0.016; 95% CI, 0.462 to 0.135, P ¼ 0.247; Fig. 5). The poor ﬁt
appears to be the result from a dramatic outlier (study by Sukhija
et al.21) in addition to a substantial scatter about the line for the
other studies. If the result of the study by Sukhija et al.21 is elimi-
nated, the meta-regression coefﬁcient is statistically signiﬁcant
(0.019; 95% CI, 0.034 to 0.003, P ¼ 0.022). On the other hand,
the coefﬁcient for the baseline diameter was statistically signiﬁcant
(0.096; 95% CI, 0.132 to 0.061; P < 0.001: Fig. 6), which indi-
cates that statin therapy is more beneﬁcial in reducing growth rate
as the baseline diameter increases. The x-axis intersection of the
95% CI upper limit was 35.9 mm, which suggests that statin therapy
is signiﬁcantly beneﬁcial in reducing growth ratewhen the baseline
diameter is 36.0 mm.
Table 1
Trial design, female percentage, follow-up duration, baseline diameter, growth rate, and their mean differences.
Study Design Adjustment
statistics
Patient
number
Female
(%)
Follow-up duration Baseline diamter (mm) Growth rate Mean difference
Statin No
statin
Statin No statin Statin No statin Unit Statin
(mean  SD)
No statin
(mean  SD)
Badger
2011
Retrospective Unadjusted 92 51 15.1 Follow-up scans (3 months apart): median,
5 (range, 2e17)
39  7 %/y 4.5  6.0a 7.5  6.0a 3.00 (95% CI,
5.05 to 0.95)a,b
Ferguson
2010
Prospective
observational
Unadjusted 349 303 6.4 Median, 5 (IQR, 3e6) years Median, 33.9
(IQR, 31.3e37.6)
Median, 33.0
(IQR, 31.0e36.5)
NA 1.63  2.846a,c 1.34  1.447a,c 0.29 (95% CI,
0.06 to 0.64)a,b
Karlsson
2009
Retrospective Unadjusted 85 127 23.5 18 months Median, 40
(range, 37e44)
mm/y 1.6  2.40a 2.5  2.40a 0.77 (95% CI,
1.5 to 0.03)a
Karrowni
2011
Retrospective Multivariate
linear
regression
136 75 33.2 Median, 1.04
(IQR, 1.01e1.10)
years
Median, 1.04
(IQR, 1.02e1.12)
years
Median, 41
(IQR, 37e44)
Median, 41
(IQR, 37e43)
%/y 0.7  12.8 7.5  9.3 8.20 (95% CI,
11.49 to 4.91)b
Mosorin
2008
Retrospective Multivariate
linear
regression
34 87 10.7 3.6  2.2 years 38.7  7.0 39.3  6.3 mm/y 1.9  1.8 2.6  2.4 0.70 (95% CI,
1.59 to 0.19)b
Periard
2012
Retrospective Multivariate
linear
regression
50 44 10.6 43  29 months 33  24 months 39.3  7.6 40.7  7.7 mm/y 2.91  2.09a 4.37  3.45a 1.06 (95% CI,
2.17 to 0.04)
Schouten
2006
Retrospective Multivariate
linear
regression
59 91 16.0 Median, 2.9 years Median, 3.2 years 40  8.5 37  7.0 mm/y 2.0  2.9a 3.6  2.9a 1.16 (95% CI,
1.99 to 0.33)
SMART
2008
Prospective
observational
Multivariate
linear
regression
63 84 10.9 Median, 3.3 (range, 0.5e11.1) years 39  6.8 mm/y NA 1.20 (95% CI,
2.34 to 0.060)
Sukhija
2006
Unclear Unadjusted 75 55 16.9 23  7 months 24  7 months 46  6 45  6 mm 1  6a,b 8  6a,b 9.0 (95% CI,
11.09 to 6.91)a,b
Sweeting
2010
Prospective
observational
Mixed-effects
linear growth
model adjusted
for potential
confounders
21 1535 32.6 Mean, 1.9 years 43  7 mm/y 1.92  2.50 2.81  2.50 0.90 (95% CI,
1.98 to 0.18)b
Thompson
2010
Prospective
observational
Flexible
hierarchical
model
383 848 5.9 Median, 3.09 (IQR, 1.97e6.05) years Median, 35 (IQR, 31e42) mm/y NA 0.29 (95% CI,
0.66 to 0.08)
Total 1347 3300
CI, conﬁdence interval; IQR, interquartile range; NA, not available; SD, standard deviation.
a Unadjusted data.
b Data calculated by us.
c Data provided directly by the authors (personal communication).
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Figure 1. Forest plot of growth rates of abdominal aortic aneurysm among patients assigned to statin therapy versus no statins from all the 11 studies (primary meta-analysis).
H. Takagi et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 287e292290Discussion
The results of our analysis suggest that statin therapy may
restrain growth of small AAAs. This result was robust in sensitivity
analyses, even eliminating unadjusted studies. The reduction in
AAA growth rate by statin therapy may prevent aneurysm rupture
or the need for repair. Despite the absence of a clear relationship
between serum cholesterol level and AAA growth rate, statin
therapy is expected to prevent AAA development, because the
pleiotropic effects of statins include an anti-inﬂammatory effect,
anti-oxidative effect, and reduction of matrix metalloproteinase
(MMP) secretion.24 Karlsson et al.25 demonstrated that patients
taking acetylsalicylic acid (ASA) had lower growth rates than those
not taking ASA (0.18 versus 0.26 cm/y; P ¼ 0.004), and that patients
taking statins and ASA together had a signiﬁcantly reduced growth
rate compared to patients who did not take statins or ASA (0.14
versus 0.27 cm/y, P < 0.001). Statins and ASA have different anti-
inﬂammatory properties, which may explain the complementary
effect, although ASA seems to be more effective than statins (0.19
versus 0.23 cm/y). In the most recent meta-analysis of 7 studies byFigure 2. Funnel plot of precision (reciprocal of standard error) by standardized mean
difference of growth rates of abdominal aortic aneurysm between patients assigned to
statin therapy versus no statins. There was no evidence of signiﬁcant publication bias
(P ¼ 0.276).Twine andWilliams,10 although there was a signiﬁcant reduction in
the AAA growth rate in patients taking statins in the overall analysis
(SMD, 0.37 mm/year; 95% CI, 0.65 to 0.08 mm/year; P ¼ 0.01),
the 4 high-quality studies (achieving at least 7 stars from
a maximum of 9 assessed using the NewcastleeOttawa Scale26) in
this analysis showed no signiﬁcant difference in AAA growth
between the 2 groups (SMD, 0.14 mm/year; 95% CI, 0.33 to
0.05 mm/year; P ¼ 0.16). The present meta-analysis, however, is
more comprehensive and includes 7 adjusted studies (reporting
adjusted growth rates or adjusted MDs of growth rates).
Among the 11 studies included in the present meta-analysis, the
greatest baseline AAA diameter (mean, 46 mm) and the most
favorable effect of statin therapy on growth rate (SMD, 1.500)
were abstracted from the study by Sukhija et al.,21 whereas the
smallest diameter (mean, 33.5 mm) and the only unfavorable effect
(SMD, 0.126) were extracted from the study by Ferguson et al.14
These ﬁndings suggest that the inhibitory effect of statin therapy
on AAA growth may depend on the baseline AAA diameter. Indeed,
our meta-regression analysis demonstrates that statin therapy is
more beneﬁcial in reducing growth rate as the baseline diameter
increases, and that statin therapy is signiﬁcantly beneﬁcial in
reducing the growth rate when the baseline diameter is 36.0 mm
(Fig. 6). Our results suggest that anti-inﬂammatory effects of statins
may contribute toward restraining AAA growth. Larger size of AAA
is likely to be associated with higher inﬂammatory status, because
of signiﬁcant positive correlations between circulating biomarkers
of inﬂammation (C-reactive protein [CRP]27 and interleukin-6
concentrations28,29) and AAA size. The absolute vascular risk
reduction associated with statin therapy (rosuvastatin within the
JUPITER trial30) is greater among those with higher baseline high-
sensitivity CRP levels. Effects of statins in reducing growth rate
may also be more beneﬁcial in AAAs with a greater baseline
diameter because of the higher inﬂammatory status. Our meta-
regression analysis also showed a trend toward more beneﬁcial
effects of statin therapy in reducing the growth rate as the
proportion of female patients increases (Fig. 5). The most recent
meta-analysis31 of 18 randomized clinical trials, however, indicated
that statins decrease cardiovascular events and all-cause mortality
similarly in women and men. Further analysis is needed in terms of
effects of statin therapy on small AAAs in female patients.
Our analysis must be viewed in the context of its limitations.
We used data from no randomized controlled trials and 11
Figure 4. One-study-removed meta-analysis of growth rates of abdominal aortic aneurysm among patients assigned to statin therapy versus no statins.
Figure 3. Forest plot of growth rates of abdominal aortic aneurysm among patients assigned to statin therapy versus no statins from the 7 high-quality studies providing adjusted
data.
Figure 5. Meta-regression plot for standardized mean difference of growth rates of
abdominal aortic aneurysm by proportion of females (%). The meta-regression coefﬁ-
cient for the female percentage (slope of the meta-regression line) was not statistically
signiﬁcant (0.016; 95% conﬁdence interval [CI], 0.462 to 0.135, P ¼ 0.247). If the
result of the study by Sukhija et al.21 is eliminated, the meta-regression coefﬁcient is
statistically signiﬁcant (0.019; 95% CI, 0.034 to 0.003, P ¼ 0.022).
H. Takagi et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 287e292 291observational comparative studies. Patients enrolled in randomized
trials may not be representative of those typically seen in clinical
practice. However, because randomized trials balance both known
and unknown confounders across treatment groups, this is the study
design least vulnerable to bias. As potential biases are likely to be
greater for observational studies compared to randomized trials,
results should always be interpreted with caution when they are
included in reviews and meta-analyses.32 Particular concerns arise
with respect to differences betweenpatients in different intervention
groups (selection bias) and studies that do not explicitly report
having had a protocol (reporting bias). Unlike for randomized trials,
it will usually be appropriate to analyze adjusted, rather than
unadjusted, effect estimates, i.e. analyses that attempt to ‘control for
confounding’. To reduce the effect of treatment-selection bias and
potential confounding in observational studies, rigorous adjustment
for signiﬁcant differences in the baseline characteristics of patients
could be conducted. Further, not unadjusted but adjusted estimates
would be pooled in a meta-analysis including observational studies.
Although we combined 4 unadjusted and 7 adjusted data sets from
observational comparative studies in the primary meta-analysis, the
sensitivity analysis of only the 7 adjusted data sets also demonstrated
a statistically signiﬁcant beneﬁt of statin therapy onAAA growth rate.
Figure 6. Meta-regression plot for standardized mean difference of growth rates of
abdominal aortic aneurysm by baseline diameter (mm). The coefﬁcient for the baseline
diameter (slope of the meta-regression line) was statistically signiﬁcant (0.096; 95%
conﬁdence interval [CI], 0.132 to 0.061; P < 0.001), and the x-axis intersection of
the 95% CI upper limit was 35.9 mm.
H. Takagi et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 287e292292Nevertheless, hidden bias may remain because of the inﬂuence of
unmeasured confounders even after appropriate adjustment.
Further, our results may be inﬂuenced by a publication bias favoring
statin therapy. This riskwasminimized through an exhaustive search
of the available literature in our analysis. Though the statistical tests
did not indicate publication bias, there is clearly limited power to
detect such bias, given the small number of studies examined.
Conclusions
We found that, based on a meta-analysis, statin therapy is likely
effective in the prevention of growth of small (<55 mm in diam-
eter) AAAs. To conﬁrm our results and more accurately assess the
effect of statins on AAA growth, however, a large randomized trial is
needed. As most patients with AAA have indications for statin
therapy, all patients should be evaluated and statin therapy should
be started if such indications are present. In the absence of indi-
cations, the use of statins could still be considered based on what
appears to be an inhibitory effect on AAA growth.
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